Contact us
Please fill out the details below and we will get back to you shortly.
Thank you!
We will be contacting you soon..
Close
We will be contacting you soon..
Oops! Something went wrong while submitting the form.
Portal Instrument's CEO, Dr. Patrick Anquetil, shares insights on reducing healthcare waste through reusable autoinjectors in a compelling OnDrug Delivery interview, "A Sustainable Future for Self-Injection with Connected, Reusable Autoinjectors."
We are thrilled to highlight a recent interview in OnDrug Delivery (Issue 171) featuring our CEO, Dr. Patrick Anquetil. Titled "A Sustainable Future for Self-Injection with Connected, Reusable Autoinjectors," the article tackles the significant environmental challenges and extensive waste generated by single-use autoinjectors in the self-injection market. Dr. Anquetil presents a compelling case for pivoting towards reusable electromechanical autoinjectors as a more sustainable and potentially cost-effective path forward. The discussion showcases Portal Instruments' solution, PRIME Nexus – a flexible, needle-based reusable platform – and explores broader insights into reducing waste, the benefits of connected reusable devices, and why sustainable innovation should ultimately lead to lower healthcare costs. The full article can be read in OnDrug Delivery.
October 2024 - At the Partnership Opportunities in Drug Delivery (PODD) conference, Robert Hidalgo showcased Portal Instrument's latest advancements on its reusable, electro-mechanical drug delivery platform.
September 8, 2020 - Portal Instruments was founded with the goal to completely disrupt how injections are given and to replace the needle and syringe with a modern, convenient and safe technology. Our Vision is a Needle-Free World.
September 2024 - Portal Instruments welcomes Matt Regan to its Board of Directors. Regan has held extensive leadership roles for prominent pharmaceutical companies such as Abbvie, Novo Nordisk and Micreos.
Please fill out the details below and we will get back to you shortly.